Clinical trial

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

NCT00299702

Study summary

ClinicalTrials.gov

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Abilify Normalized identity: Abilify View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Risperidal Consta Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-02-01

PhasePHASE4

Conditions

Schizophreniaverified · MONDO: schizophrenia

Psychotic Disordersunresolved

Interventions

AbilifyDRUG · verified · RxNorm: Abilify

Risperidal ConstaDRUG

Sponsors & collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.lead sponsor

Janssen, LPcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00299702 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.